Revenue at nine months: +21% - Continued growth

07/17/2014
In EUR millions 2006 2007 Change 2007/2006 Change 2007/proforma 2006* at constant USD
First quarter 18.3 21.2 + 15.6 % + 12.1 %
Second quarter 16.3 20.6 + 26.4 % + 15.8 %
Third quarter 15.1 18.3 + 21.7 % + 12.2 %
9 months 49.7 60.1 + 21.0 % + 13.4 %

* With the integration of Hammer Pharma from January 1, 2006 and HP Botanicals from April 1, 2006

Naturex continued to enjoy sustained growth over the third quarter of 2007, posting revenues of EUR 18.3 million, up 21.7 %.

Revenues for the first nine months of the year stood at EUR 60.1 million, up 21.0 %. Proforma growth stood at 13.4% at constant USD rates and 7.7% at current USD rates.

Accordingly, Naturex's activity over the first nine months of the year is in with its development plan as the Group pursues its aggressive commercial strategy against a buoyant market backdrop.

Naturex will report its 2007 full-year revenues on January 28, 2008.

If you would like to receive free financial information about Naturex by e-mail, contact: www.kaparcafinance.com

NATUREX has been listed since October 1996
 Eurolist by Euronext Paris, segment B, ISIN: FR0000054694, Reuters NATU.LN. Bloomberg NTRX

Contacts

NATUREX
 Jacques Dikansky – Président Directeur Général
 Tél. : +33 4 90 23 96 89 /j.dikansky@naturex.com
 
 Thierry Lambert – Directeur Général Adjoint
 Tél. : +33 4 90 23 96 89 / t.lambert@naturex.com
ACTUS
 Agnès Gilbert – Relations presse
 Tél. : +33 1 53 67 36 33 / agilbert@actus.fr
 
 KAPARCA FINANCE
 Laurence Marquézy – Relations investisseurs
 Tél. : +33 1 72 74 82 23 / lmarquezy@kaparcafinance.com
actu_26_Fichierpdf.pdf
 
of 233
BACK